Back

Undertreatment of women with lipid-lowering therapies in four European countries: results from the prospective, non-interventional MILOS Study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing? Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Ioanna Gouni-Berthold

University of Cologne, Cologne (Germany)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Professor S. Mulvagh (Halifax, CA)
Abstract Slides Video
Presentation thumbnail
Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT
Doctor D. Bhatt (New York City, US)
Abstract Slides Video

Access the full session

Session thumbnail
Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Session
Dyslipidaemia: novel diagnostics and therapy options

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources